Thursday, 20 October 2011

Researchers observed both remyelination indicative of repair and a drastic reduction of demyelination and axonal loss in mice treated with COPAXONE(R).

(NASDAQ: TEVA) today announced preclinical data demonstrating reparative and neuroprotective effects of treatment with COPAXONE(R) (glatiramer acetate injection) in experimental autoimmune encephalomyelitis (EAE) models. In the study, researchers compared mice treated with COPAXONE(R) versus non-treated mice in relapsing-remitting and chronic multiple sclerosis (MS) disease models.  Read more here.